A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2009
11/17/2009	US7618629 Manipulation of cytokine levels using CD83 gene products
11/17/2009	US7618623 Hybrid adeno-retroviral vector for the transfection of cells
11/17/2009	US7618621 Preparing culture of pluripotent brain tissue for nervous tissue regeneration, tissue engineering and treating nervous system disorders
11/17/2009	US7618620 Artificial tears or vehicles for ophthalmic drugs; viscosity; hydroxypropyl methylcellulose and a combination of two other polymers: guar gum, a carboxyvinyl polymer (polymer of acrylic acid crosslinked with allyl sucrose or allylpentaerythritol), hydroxyethyl cellulose or dextran
11/17/2009	US7618619 For use in ocular surgery; containing a vital dyes, especially a disazo dye, that does not diffuse out of the visco-elastic composition.
11/17/2009	US7618616 Sulfur mustard gas injury and/or VX intoxication; hydrophilic glycerin-based cream mixture with polyols; mono-, oligo- or polysaccharides and/or salts;
11/17/2009	CA2588495C The utility of uridine nucleosides in the treatment of cachexia
11/17/2009	CA2554346C Parenteral formulations comprising a beta-cyclodextrin and a preservative
11/17/2009	CA2535511C Compounds having thrombopoietin receptor agonism
11/17/2009	CA2522051C Diamine derivative, production process therefor and antioxidant
11/17/2009	CA2521950C Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
11/17/2009	CA2510949C Polymorph of ritonavir
11/17/2009	CA2470519C Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5
11/17/2009	CA2463272C Piperazine derivatives with ccr1 receptor antagonist activity
11/17/2009	CA2450801C Drugs that enhance synaptic responses mediated by ampa receptors
11/17/2009	CA2444501C Phenylindoles for the treatment of hiv
11/17/2009	CA2443636C Remedial agent for chronic articular rheumatism
11/17/2009	CA2441239C Mch antagonists and their use in the treatment of obesity
11/17/2009	CA2432181C Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists
11/17/2009	CA2422925C .delta.1-pyrrolines used as pesticides
11/17/2009	CA2417082C New benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
11/17/2009	CA2411368C Therapeutic combinations of fatty acids
11/17/2009	CA2411172C Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase i and ii inhibitors
11/17/2009	CA2407094C Diazabicyclic central nervous system active agents
11/17/2009	CA2406269C Process for drying amoxicillin
11/17/2009	CA2402524C Methods of making and using 7.alpha.,11.beta.-dimethyl-17.beta.-hydroxy-4-estren-3-one 17.beta.-trans-4-n-butylcyclohexane carboxylate and 7.alpha.,11.beta.-dimethyl-17.beta.-hydroxyestr-4-en-3-one 17-undecanoate
11/17/2009	CA2399299C Compounds with chelation affinity and selectivity for first transition series elements and their use
11/17/2009	CA2398992C Therapeutic or preventive agent for pulmonary insufficiency containing a diaminotrifluoromethylpyridine derivative
11/17/2009	CA2397450C Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
11/17/2009	CA2397244C Ace inhibitor-vasopressin antagonist combinations
11/17/2009	CA2393809C Heterocyclic dihydropyrimidines as potassium channel inhibitors
11/17/2009	CA2383364C Methods of preparing substituted tetracyclines with transition metal-based chemistries
11/17/2009	CA2382296C Selective cox-2 inhibitory novel esters from indolealkanols and novel amides from indolealkylamines
11/17/2009	CA2379365C Transnasal anticonvulsive compositions and modulated process
11/17/2009	CA2376850C Topical formulations comprising skin penetration agents and the use thereof
11/17/2009	CA2374606C Transdermal device for the application of testosterone or one of the derivatives thereof
11/17/2009	CA2374158C Indole derivatives
11/17/2009	CA2372691C Antifungal ethers
11/17/2009	CA2370791C Process of making carboxylated dextran
11/17/2009	CA2369997C Compositions and methods for treating amyloidosis
11/17/2009	CA2366897C Immunomodulatory compositions and methods of use thereof
11/17/2009	CA2353529C Method for reducing free-radical induced injury
11/17/2009	CA2352494C Compositions and methods for the treatment of alzheimer's disease, central nervous system injury, and inflammatory diseases
11/17/2009	CA2351814C Taste masked pharmaceutical particles
11/17/2009	CA2339090C Methimazole derivatives and tautomeric cyclic thiones to treat autoimmune diseases
11/17/2009	CA2338457C Preparation of aqueous clear solution dosage forms with bile acids
11/17/2009	CA2336822C Method of treatment and pharmaceutical composition
11/17/2009	CA2321198C 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives as muscarinic receptor antagonists
11/17/2009	CA2301739C Optically pure camptothecin analogues, optically pure synthesis intermediate and method for preparing same
11/17/2009	CA2291754C Smad-interacting polypeptides and their use
11/17/2009	CA2288694C Active vitamin d3 emulsion lotion
11/17/2009	CA2272460C Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine
11/17/2009	CA2265952C Injection formulations of avermectins and milbemycins
11/17/2009	CA2262600C Stanol composition and the use thereof
11/17/2009	CA2259583C Azolo triazines and pyrimidines
11/17/2009	CA2254394C Method and composition for the treatment and prevention of hyperuricemia
11/17/2009	CA2249181C Scf analog compositions and methods
11/17/2009	CA2248418C Food containing biotin and one or more other b vitamins
11/17/2009	CA2230949C Synthetic peptides that inhibit il-6 activity
11/17/2009	CA2208246C Formulations and methods for reducing skin irritation
11/17/2009	CA2206794C Novel 3,5-dioxo-(2h,4h)-1,2,4-triazine derivatives, their preparation and use as drugs
11/17/2009	CA2206515C Identification of genes which allow a microorganism to adapt to a particular environment
11/17/2009	CA2166079C Chemically modified oligonucleotide for site-directed mutagenesis
11/17/2009	CA2157577C Growth differentiation factor-8
11/17/2009	CA2116327C Method and compositions for cellular reprogramming
11/16/2009	CA2666036A1 Novel compositions and methods for treating hyperproliferative diseases
11/12/2009	WO2009137843A2 Nmda receptor antagonists for the treatment of neuropsychiatric disorders
11/12/2009	WO2009137827A2 Controlled release of n-acetylcysteine (nac) for reduction of systemic and/or vascular inflammation
11/12/2009	WO2009137818A1 Methods for preventing and treating neurodegenerative diseases
11/12/2009	WO2009137782A2 Allosteric enhancers of the a1 adenosine receptor
11/12/2009	WO2009137739A1 Processes for the preparation of o-[5-[4-amino-thiazol-2-yl]-pyridin-2-ylmethyl]-hydroxylamine
11/12/2009	WO2009137737A2 Anti-bacterial activity of 9-hydroxy derivatives of 6, 11-bicyclolides
11/12/2009	WO2009137733A1 Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction
11/12/2009	WO2009137732A1 Adatanserin and metabolites thereof for treatment of attention deficit disorder, anxiety, depression, sexual dysfunction, and other disorders
11/12/2009	WO2009137728A2 Method for producing bicyclic guanidines by use of a cyclic urea
11/12/2009	WO2009137717A1 Novel nitroso compounds as nitroxyl donors and methods of use thereof
11/12/2009	WO2009137681A1 Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds
11/12/2009	WO2009137679A1 3-hydroxy gepirone for the treatment of attention deficit disorder and sexual dysfunction
11/12/2009	WO2009137660A2 Enhancement of drug therapy by mirna
11/12/2009	WO2009137657A1 2-aryl glycinamide derivatives
11/12/2009	WO2009137649A2 Methods for treating thyroid cancer
11/12/2009	WO2009137611A2 Treatment of pulmonary fungal infection with voriconazole via inhalation
11/12/2009	WO2009137603A1 Ophthalmic device, and method of use thereof, for increasing ocular boundary lubrication
11/12/2009	WO2009137602A1 Therapeutic modulation of ocular surface lubrication
11/12/2009	WO2009137597A1 COMPOUNDS THAT INHIBIT PRODUCTION OF sAPPβ AND Aβ AND USES THEREOF
11/12/2009	WO2009137596A1 Substituted amides, method of making, and use as btk inhibitors
11/12/2009	WO2009137544A1 Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds
11/12/2009	WO2009137534A2 Estrogenic extracts for use in treating vaginal and vulvar atrophy
11/12/2009	WO2009137533A2 Ameliorating nervous systems disorders
11/12/2009	WO2009137531A2 Compositions and methods related to action of low dosages of doxepin on the h1 and 5-ht2a receptors
11/12/2009	WO2009137527A1 1-methylnicotinamide analogs
11/12/2009	WO2009137510A2 Method for protecting humans against superficial vasodilator flush syndrome
11/12/2009	WO2009137503A1 Hdac inhibitors and uses thereof
11/12/2009	WO2009137500A1 6-substituted benzofuran compounds to treat infection with hepatitis c virus
11/12/2009	WO2009137499A1 Inhibitors of histone deacetylase
11/12/2009	WO2009137493A1 2-substituted benzofuran compounds to treat infection with hepatitis c virus
11/12/2009	WO2009137492A1 Heteroaryl-fused macrocyclic pyrimidine derivatives
11/12/2009	WO2009137471A2 Azo dye related small molecule modulators of protein-protein interactions
11/12/2009	WO2009137465A2 Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure
11/12/2009	WO2009137462A2 Methods for treating cognitive disorders using inhibitors of histone deacetylase

1 ... 2501 2502 2503 2504 2505 2506 2507 2508 2509 2510 2511 2512 2513 2514 2515 2516 2517 2518 2519 2520 2521 ... 7860